Loading…

Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus

Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increa...

Full description

Saved in:
Bibliographic Details
Published in:Virology journal 2020-12, Vol.17 (1), p.191-191, Article 191
Main Authors: Huang, Jingjin, Huang, Nan, Fan, Menglu, Zhao, Lingcai, Luo, Yan, Ding, Pingyun, Tian, Miao, Liu, Qingzheng, Guo, Yanna, Zhao, Jinhua, Zheng, Yiqing, Zhang, Haitao, Ping, Jihui
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253
container_end_page 191
container_issue 1
container_start_page 191
container_title Virology journal
container_volume 17
creator Huang, Jingjin
Huang, Nan
Fan, Menglu
Zhao, Lingcai
Luo, Yan
Ding, Pingyun
Tian, Miao
Liu, Qingzheng
Guo, Yanna
Zhao, Jinhua
Zheng, Yiqing
Zhang, Haitao
Ping, Jihui
description Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important. A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments. The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was NAELLVL in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy. Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.
doi_str_mv 10.1186/s12985-020-01458-z
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_50bded29466f463aa6406f3f72330a00</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A650619281</galeid><doaj_id>oai_doaj_org_article_50bded29466f463aa6406f3f72330a00</doaj_id><sourcerecordid>A650619281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7jr6B7yQgjd60TVfTdobYVjUHVgQ_ADvwmmS1oxpMybp4MyvN7OzrjsiuUg4ec57kpe3KJ5jdIFxw99ETNqmrhBBFcKsbqr9g-IcC0YrRsi3h_fOZ8WTGNcIUcJF-7g4o5Q0omHtebG-MiMMg5uTnexUxgTuR9VBNLoc_eSV8xO4EqZkO693pXFW2RTLLnjQblcGAyrZrU27EgawU0zlEPy8KXFpp97NZtpDuSy3NszxafGoBxfNs9t9UXx9_-7L5VV1_fHD6nJ5XamaNakC6ATua9ZRiqBvmdZaUCHqzhjFNGlaZfLrVW00Bk6paGtBQDChmo6QntR0UayOutrDWm6CHSHspAcrbwo-DBJCssoZWaNOG01axnnPOAXgDPGe9oIchme_FsXbo9Zm7kajlZlSAHcienoz2e9y8FspBEGIHx7z6lYg-J-ziUmONirjHEzGz1ESxhtKeWYz-vIfdO3nkO0_UAITjNum-UsNkD-QTfZ5rjqIyiWvEcctaXCmLv5D5aXNaJWfTG9z_aTh9UlDZpL5lQaYY5Srz59OWXJkVfAxBtPf-YGRPCRTHpMpczLlTTLlPje9uO_kXcufKNLf1E3eeA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471211988</pqid></control><display><type>article</type><title>Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Huang, Jingjin ; Huang, Nan ; Fan, Menglu ; Zhao, Lingcai ; Luo, Yan ; Ding, Pingyun ; Tian, Miao ; Liu, Qingzheng ; Guo, Yanna ; Zhao, Jinhua ; Zheng, Yiqing ; Zhang, Haitao ; Ping, Jihui</creator><creatorcontrib>Huang, Jingjin ; Huang, Nan ; Fan, Menglu ; Zhao, Lingcai ; Luo, Yan ; Ding, Pingyun ; Tian, Miao ; Liu, Qingzheng ; Guo, Yanna ; Zhao, Jinhua ; Zheng, Yiqing ; Zhang, Haitao ; Ping, Jihui</creatorcontrib><description>Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important. A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments. The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was NAELLVL in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy. Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.</description><identifier>ISSN: 1743-422X</identifier><identifier>EISSN: 1743-422X</identifier><identifier>DOI: 10.1186/s12985-020-01458-z</identifier><identifier>PMID: 33287849</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Antigenic drift ; Avian flu ; Broad-spectrum ; Epitope ; Epitopes ; Genetic aspects ; Genomes ; HA protein ; HA2 stalk region antibody ; Health aspects ; Hemagglutinins ; Immunosurveillance ; Influenza A ; Influenza virus ; Influenza viruses ; Lethal dose ; Lymphocytes ; Membranes ; Molecular diagnostic techniques ; Monoclonal antibodies ; Pandemics ; Plasmids ; Proteins ; Public health ; Vaccines ; Viral proteins ; Virus research ; Viruses</subject><ispartof>Virology journal, 2020-12, Vol.17 (1), p.191-191, Article 191</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720065/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2471211988?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33287849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Jingjin</creatorcontrib><creatorcontrib>Huang, Nan</creatorcontrib><creatorcontrib>Fan, Menglu</creatorcontrib><creatorcontrib>Zhao, Lingcai</creatorcontrib><creatorcontrib>Luo, Yan</creatorcontrib><creatorcontrib>Ding, Pingyun</creatorcontrib><creatorcontrib>Tian, Miao</creatorcontrib><creatorcontrib>Liu, Qingzheng</creatorcontrib><creatorcontrib>Guo, Yanna</creatorcontrib><creatorcontrib>Zhao, Jinhua</creatorcontrib><creatorcontrib>Zheng, Yiqing</creatorcontrib><creatorcontrib>Zhang, Haitao</creatorcontrib><creatorcontrib>Ping, Jihui</creatorcontrib><title>Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus</title><title>Virology journal</title><addtitle>Virol J</addtitle><description>Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important. A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments. The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was NAELLVL in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy. Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.</description><subject>Antigenic drift</subject><subject>Avian flu</subject><subject>Broad-spectrum</subject><subject>Epitope</subject><subject>Epitopes</subject><subject>Genetic aspects</subject><subject>Genomes</subject><subject>HA protein</subject><subject>HA2 stalk region antibody</subject><subject>Health aspects</subject><subject>Hemagglutinins</subject><subject>Immunosurveillance</subject><subject>Influenza A</subject><subject>Influenza virus</subject><subject>Influenza viruses</subject><subject>Lethal dose</subject><subject>Lymphocytes</subject><subject>Membranes</subject><subject>Molecular diagnostic techniques</subject><subject>Monoclonal antibodies</subject><subject>Pandemics</subject><subject>Plasmids</subject><subject>Proteins</subject><subject>Public health</subject><subject>Vaccines</subject><subject>Viral proteins</subject><subject>Virus research</subject><subject>Viruses</subject><issn>1743-422X</issn><issn>1743-422X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl2L1DAUhoso7jr6B7yQgjd60TVfTdobYVjUHVgQ_ADvwmmS1oxpMybp4MyvN7OzrjsiuUg4ec57kpe3KJ5jdIFxw99ETNqmrhBBFcKsbqr9g-IcC0YrRsi3h_fOZ8WTGNcIUcJF-7g4o5Q0omHtebG-MiMMg5uTnexUxgTuR9VBNLoc_eSV8xO4EqZkO693pXFW2RTLLnjQblcGAyrZrU27EgawU0zlEPy8KXFpp97NZtpDuSy3NszxafGoBxfNs9t9UXx9_-7L5VV1_fHD6nJ5XamaNakC6ATua9ZRiqBvmdZaUCHqzhjFNGlaZfLrVW00Bk6paGtBQDChmo6QntR0UayOutrDWm6CHSHspAcrbwo-DBJCssoZWaNOG01axnnPOAXgDPGe9oIchme_FsXbo9Zm7kajlZlSAHcienoz2e9y8FspBEGIHx7z6lYg-J-ziUmONirjHEzGz1ESxhtKeWYz-vIfdO3nkO0_UAITjNum-UsNkD-QTfZ5rjqIyiWvEcctaXCmLv5D5aXNaJWfTG9z_aTh9UlDZpL5lQaYY5Srz59OWXJkVfAxBtPf-YGRPCRTHpMpczLlTTLlPje9uO_kXcufKNLf1E3eeA</recordid><startdate>20201207</startdate><enddate>20201207</enddate><creator>Huang, Jingjin</creator><creator>Huang, Nan</creator><creator>Fan, Menglu</creator><creator>Zhao, Lingcai</creator><creator>Luo, Yan</creator><creator>Ding, Pingyun</creator><creator>Tian, Miao</creator><creator>Liu, Qingzheng</creator><creator>Guo, Yanna</creator><creator>Zhao, Jinhua</creator><creator>Zheng, Yiqing</creator><creator>Zhang, Haitao</creator><creator>Ping, Jihui</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20201207</creationdate><title>Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus</title><author>Huang, Jingjin ; Huang, Nan ; Fan, Menglu ; Zhao, Lingcai ; Luo, Yan ; Ding, Pingyun ; Tian, Miao ; Liu, Qingzheng ; Guo, Yanna ; Zhao, Jinhua ; Zheng, Yiqing ; Zhang, Haitao ; Ping, Jihui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antigenic drift</topic><topic>Avian flu</topic><topic>Broad-spectrum</topic><topic>Epitope</topic><topic>Epitopes</topic><topic>Genetic aspects</topic><topic>Genomes</topic><topic>HA protein</topic><topic>HA2 stalk region antibody</topic><topic>Health aspects</topic><topic>Hemagglutinins</topic><topic>Immunosurveillance</topic><topic>Influenza A</topic><topic>Influenza virus</topic><topic>Influenza viruses</topic><topic>Lethal dose</topic><topic>Lymphocytes</topic><topic>Membranes</topic><topic>Molecular diagnostic techniques</topic><topic>Monoclonal antibodies</topic><topic>Pandemics</topic><topic>Plasmids</topic><topic>Proteins</topic><topic>Public health</topic><topic>Vaccines</topic><topic>Viral proteins</topic><topic>Virus research</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Jingjin</creatorcontrib><creatorcontrib>Huang, Nan</creatorcontrib><creatorcontrib>Fan, Menglu</creatorcontrib><creatorcontrib>Zhao, Lingcai</creatorcontrib><creatorcontrib>Luo, Yan</creatorcontrib><creatorcontrib>Ding, Pingyun</creatorcontrib><creatorcontrib>Tian, Miao</creatorcontrib><creatorcontrib>Liu, Qingzheng</creatorcontrib><creatorcontrib>Guo, Yanna</creatorcontrib><creatorcontrib>Zhao, Jinhua</creatorcontrib><creatorcontrib>Zheng, Yiqing</creatorcontrib><creatorcontrib>Zhang, Haitao</creatorcontrib><creatorcontrib>Ping, Jihui</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Virology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Jingjin</au><au>Huang, Nan</au><au>Fan, Menglu</au><au>Zhao, Lingcai</au><au>Luo, Yan</au><au>Ding, Pingyun</au><au>Tian, Miao</au><au>Liu, Qingzheng</au><au>Guo, Yanna</au><au>Zhao, Jinhua</au><au>Zheng, Yiqing</au><au>Zhang, Haitao</au><au>Ping, Jihui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus</atitle><jtitle>Virology journal</jtitle><addtitle>Virol J</addtitle><date>2020-12-07</date><risdate>2020</risdate><volume>17</volume><issue>1</issue><spage>191</spage><epage>191</epage><pages>191-191</pages><artnum>191</artnum><issn>1743-422X</issn><eissn>1743-422X</eissn><abstract>Influenza virus remains a continuous and severe threat to public health worldwide, and its prevention and treatment have always been a major international issue. Because of its ability to evade immune surveillance through rapid antigenic drift and antigenic shift, broad-spectrum vaccines seem increasingly important. A mAb named 3C12 from an immortalized hybrid cell was generated via immunizing mice with HA2 protein from A/chicken/Anhui/BRI99/2016 (AH/BRI99/16, H9N2) generated by prokaryotic expression. Then, its broad-spectrum activity was analyzed by WB and IFA. Next, the minimal linear epitope was identified via analyzing the reaction of a series of HA truncations with 3C12. Finally, the protective effects of 3C12 were evaluated in vitro and in vivo infection experiments. The mAb could react with the viruses of subtypes H1, H2, H5, H8, H9, H12, H13, H16, and HA protein of H18 in group 1, but failed to react with viruses in group 2. The minimal linear epitope targeted by the mAb was NAELLVL in full length of HA and localized in the C-helix region of HA2 (residue 95-101, HA2 numbering). What's more, the mAb 3C12 inhibited H1, H2, H5, H8, H9, H12, H13 and H16 virus-replication in vitro and also has shown effectiveness in preventing and treating disease in mice challenged with lethal dose of AH/BRI99/16 (H9N2) virus in vivo. These results suggested that the broadly reactive anti-HA stem mAb 3C12 exhibited prophylactic and therapeutic efficacy. Here, we have demonstrated that the linear epitope identified in this study could be a novel target for developing broad-spectrum influenza diagnostics or vaccine design, and the HA2-based monoclonal antibody is indeed a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>33287849</pmid><doi>10.1186/s12985-020-01458-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1743-422X
ispartof Virology journal, 2020-12, Vol.17 (1), p.191-191, Article 191
issn 1743-422X
1743-422X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_50bded29466f463aa6406f3f72330a00
source Publicly Available Content Database; PubMed Central
subjects Antigenic drift
Avian flu
Broad-spectrum
Epitope
Epitopes
Genetic aspects
Genomes
HA protein
HA2 stalk region antibody
Health aspects
Hemagglutinins
Immunosurveillance
Influenza A
Influenza virus
Influenza viruses
Lethal dose
Lymphocytes
Membranes
Molecular diagnostic techniques
Monoclonal antibodies
Pandemics
Plasmids
Proteins
Public health
Vaccines
Viral proteins
Virus research
Viruses
title Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A54%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemagglutinin%20stalk-based%20monoclonal%20antibody%20elicits%20broadly%20reactivity%20against%20group%201%20influenza%20A%20virus&rft.jtitle=Virology%20journal&rft.au=Huang,%20Jingjin&rft.date=2020-12-07&rft.volume=17&rft.issue=1&rft.spage=191&rft.epage=191&rft.pages=191-191&rft.artnum=191&rft.issn=1743-422X&rft.eissn=1743-422X&rft_id=info:doi/10.1186/s12985-020-01458-z&rft_dat=%3Cgale_doaj_%3EA650619281%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c548t-aab71f54b330af94ddd73775beec4d289ce328c5ed1a63379572a747c8b22f253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2471211988&rft_id=info:pmid/33287849&rft_galeid=A650619281&rfr_iscdi=true